Nucleotide sequences coding for variable regions of β chains of human T lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic uses

• US 7,294,712 B2
• Filed: 03/12/2002
• Issued: 11/13/2007
• Est. Priority Date: 06/04/1990
• Status: Expired due to Fees

• Current Assignee: Aventis Pharma SA (Sanofi )
• Original Assignee: Aventis Pharma SA (Sanofi )
• Inventors: Hercend, Thierry, Triebel, Frederic, Roman-Roman, Sergio, Ferradini, Laurent
• Primary Examiner(s): MCGARRY, SEAN
• Application Number:
  US10/095,672
• Publication Number:
  US 20030068628A1
• Time in Patent Office: 2,072 Days
• Field of Search: 435/6, 536/23.1, 536/24.3
• US Class Current: 536/24.5
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: C07K 14/7051 T-cell receptor (TcR)-CD3 complex
• CPC Class Codes: C07K 16/2809 against the T-cell receptor (TcR)-CD3 complex
• CPC Class Codes: C12N 15/1138 against receptors or cell surface proteins

Abstract

The present invention relates to new nucleotide sequences coding for variable regions of β chains of human T lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic uses.

Claims

1. A composition containing an antisense oligonucleotide of at least 10 consecutive nucleotides of a V_β

segment of SEQ ID NO;

7.

2. A composition according to claim 1 wherein the antisense oligonucleotide comprises at least 16 consecutive nucleotides.

3. A composition according to claim 1 wherein the antisense oligonucleotide consists of the entire antisense sequence of the sequences of a V_β

segment of SEQ ID NO;

7 or nucleotides 1 to 155 of SEQ ID NO;

7.

4. A composition according to claim 1 wherein the antisense oligonucleotide comprises at least 10 consecutive nucleotides of a V_β

segment of nucleotides 1 to 155 of SEQ ID NO;

7.

5. A composition according to claim 4 wherein the antisense oligonucleotide comprises at least 16 consecutive nucleotides of a V_β

segment of nucleotides 1 to 155 of SEQ ID NO;

7.